Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial in Patients With Severe Tricuspid Regurgitation

Tricuspid Regurgitation Clinical Trial

Official title:

Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial (NoTR): A Trial to Evaluate the Safety and Effectiveness of Transcatheter Valve Edge-to-edge Repair System in Patients With Severe Tricuspid Regurgitation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05497141
• Other study ID #: 2022YLK17
• Status: Recruiting
• Phase: N/A
• Start date: July 22, 2022
• Est. completion date: October 22, 2023

Study information

• Verified date: August 2022
• Source: Xiamen Cardiovascular Hospital, Xiamen University
• Contact: Xiang Chen, Dr
• Phone: 18033997788
• Email: Seanchenx[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and effectiveness of Dawneo Neoblazar® transcatheter tricuspid valve edge-to-edge repair system in patients with severe tricuspid regurgitation.

This is a prospective, multicenter, randomized, objective performance criteria trial. 98 patients who meet the inclusion criteria will be included in the study. This study will be conducted in in each site as run-in subjects. Subjects who meet the requirements and who voluntarily participate in the trial and sign the informed consent form, will be implanted with the Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System.

Description:

OBJECTIVES：To evaluate the safety and effectiveness of Dawneo Neoblazar® transcatheter tricuspid valve edge-to-edge repair system in patients with severe tricuspid regurgitation.

CLINICAL INVESTIGATION POPULATION:Patients who are on echocardiographic evidence of severe tricuspid regurgitation.

CLINICAL INVESTIGATION DESIGN:This is a prospective, multicenter, single arm, objective performance criteria trial. 98 patients who meet the inclusion criteria will be included in the study. This study will be conducted in in each site as run-in subjects. Subjects who meet the requirements and who voluntarily participate in the trial and sign the informed consent form, will be implanted with the Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 98
• Est. completion date: October 22, 2023
• Est. primary completion date: August 22, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects of age > 18 years;

2. Subjects suffering from severe tricuspid regurgitation (TR=3+), defined by TTE or TEE;

3. Subject has symptoms with NYHA = Class II-Iva, or at least one hospitalization for symptoms of heart failure during the past 12 months.

4. Subjects with two cardiac surgeons agreements of contraindications to surgery or high risk, who meets at least one of the following three conditions:

? Euroscore=8%;

? Presence of 2 or more Frailty Index;

? Presence of 2 or more organ insufficiencies?

5. Subjects who's tricuspid valve anatomy are suitable for transcatheter valve edge-to-edge repairment as assessed.

6. Subjects agreeing to the scheduled follow up requirements, who can understand the purpose of the clinical investigation, and sign voluntarily the informed consent form by themselves and/or the subject' legal guardians.

Exclusion Criteria:

1. Pulmonary artery systolic pressure >70 mmHg measured by transthoracic echocardiography or right heart catheterization, or irreversible precapillary pulmonary hypertension;

2. The presence of calcification in the grasping area of the tricuspid valve leaflets (including the anterior, septal, and posterior leaflets) that affects clamping, and the thickness of the tricuspid valve leaflets=4mm;

3. Severe tricuspid leaflet perforation, cleft or other lesions which preventing the implantation;

4. Tricuspid valve leaflets coaptation gap >7mm

5. Tricuspid stenosis as assessed by echocardiography (defined as tricuspid orifice area =1.0 cm2)

6. LVEF=20%;

7. Refractory heart failure requiring advanced intervention (e.g., left ventricular assist device, heart transplantation, etc.) (ACC/AHA stage D heart failure);

8. Myocardial infarction or unstable angina within 4 weeks;

9. Untreated severe coronary artery stenosis requiring revascularization;

10. Received percutaneous coronary intervention within 1 month prior to implantation;

11. Severe and uncontrolled hypertension: SBP=180mmHg or DBP=110mmHg;

12. Previously implantation of tricuspid valve, annuloplasty ring or accepted tricuspid valve repair surgery;

13. Pacemaker leads or ICD leads that may affect implantation

14. Complications of other cardiac diseases requiring surgical intervention;

15. Tricuspid leaflet lesions due to rheumatic heart disease (e.g., leaflet grossness, thickening, poor compliance, etc.);

16. Combined with moderate or severer aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation;

17. Congenital Ebstein malformation;

18. Presents of thrombus, vegetation, mass in the right heart system, femoral vein or inferior vena cava, etc.

19. Hemorrhagic disease or hypercoagulable state;

20. Contraindication or allergic reaction to dual antiplatelet agents and anticoagulants;

21. Active infection requiring antibiotic treatment;

22. Renal failure, requiring dialysis treatment;

23. Severe terminal illness (e.g., cancer, etc.) with a life expectancy of less than 1 year;

24. Pregnant, lactating women, women preparing to conceive or women of childbearing age with a positive HCG test (except for women whose medical history describes menopause);

25. Subjects have not met the observed endpoint in other clinical studies in which they participated;

26. Inability to comply with the clinical investigation follow-up or other clinical investigation requirements.

Related Conditions & MeSH terms

• Tricuspid Regurgitation
• Tricuspid Valve Insufficiency

Intervention

Device:
• Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System
Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.

Locations

Country	Name	City	State
China	Xiamen Cardiovascular Hospital Xiamen University	Xiamen	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Xiamen Cardiovascular Hospital, Xiamen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Implantation Success	No all-cause mortality after implantation; No tricuspid open surgery after implantation; tricuspid regurgitation reduction at least 1 grade.	12 months
Secondary	Initial Success	The device was successfully delivered to the target position and successfully released, and the delivery system was successfully withdrawn from the body without any detachment incident.	1 week
Secondary	NYHA Functional Class	New York Heart Association functional class(NYHA). Number of Improvement in NYHA classification is defined as a reduction in NYHA classification of at least 1 grade from baseline by Core Lab assessment.	30 days, 6 months, 12 months, annual for five years
Secondary	Six-minute walk test	Change in distence(m) from baseline	30 days, 6 months, 12 months, annual for five years
Secondary	Reduction in TR grade	Number of patients with reduction in TR from baseline by Core Lab assessment	30 days, 6 months, 12 months, annual for five years